HCPCS Level II code J2356 identifies the injectable biologic tezepelumab-ekko, billed per 1 mg unit. This code is used when recording drug supply for tezepelumab-ekko, a monoclonal antibody therapy with applications in certain inflammatory and respiratory conditions. Nationally, accurate reporting of J2356 is important for clinical documentation, reimbursement, drug utilization monitoring, and budget planning for providers and payers.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of what J2356 represents, typical sites of service for administration, and the payer landscape that shapes coverage and billing practices. The publication covers billing benchmarks, common payer policies and coverage considerations, and the clinical context for tezepelumab-ekko use. It also highlights typical billing patterns and coding nuances relevant to hospital outpatient departments and physician offices.

This summary is intended for national audiences involved in medical billing, revenue cycle management, payer policy, and clinical program planning who need a clear, practical reference for HCPCS Level II code J2356.